Laura Kohtamäki

University of Helsinki

Finland

Research Interests

Explore related searches

Professors in Finland Professors in Immunology Immunology professors in Finland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (9)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

Mariliina Arjama

University of Helsinki

FINLAND

View details

Sirpa Leppä

University of Helsinki

FINLAND

View details

Daniela Ungureanu

Associate Prof. (tenure)

University of Oulu

FINLAND

View details

Micaela Hernberg

Associate professor

University of Helsinki

FINLAND

View details

Astrid Murumägi

University of Helsinki

FINLAND

View details

Kalle E. Mattila

Helsinki University Hospital

FINLAND

View details

Henna Kasanen

University of Helsinki

FINLAND

View details

Teemu Daniel Laajala

Docent (Associate / Adjunct Professor)

University of Turku

FINLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Laura Kohtamäki

Research Interests

Explore related searches

Contact this professor

Articles (9)

Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy

Intra-patient evolution of tumor microenvironment in the pathogenesis of treatment-naïve metastatic melanoma patients

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor

Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs

BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

Limited-duration anti-PD-1 therapy for patients with metastatic melanoma

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Collaborators (8)

Mariliina Arjama

Sirpa Leppä

Daniela Ungureanu

Micaela Hernberg

Astrid Murumägi

Kalle E. Mattila

Henna Kasanen

Teemu Daniel Laajala

Make your next move.